Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) saw a significant drop in short interest in December. As of December 29th, there was short interest totalling 851,483 shares, a drop of 4.5% from the December 15th total of 891,694 shares. Based on an average daily trading volume, of 104,314 shares, the short-interest ratio is currently 8.2 days. Approximately 9.1% of the company’s stock are sold short.
Separately, HC Wainwright set a $5.00 price target on Ampliphi Biosciences and gave the company a “buy” rating in a research note on Wednesday, November 15th.
Ampliphi Biosciences (NYSEAMERICAN:APHB) opened at $1.12 on Friday. The stock has a market capitalization of $10.64, a PE ratio of -0.11 and a beta of 2.93. Ampliphi Biosciences has a twelve month low of $0.67 and a twelve month high of $6.80.
COPYRIGHT VIOLATION NOTICE: This report was posted by Stock Observer and is the sole property of of Stock Observer. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.thestockobserver.com/2018/01/14/ampliphi-biosciences-corp-aphb-short-interest-update.html.
About Ampliphi Biosciences
AmpliPhi Biosciences Corporation is a biotechnology company. The Company is focused on the discovery, development and commercialization of phage therapeutics. The Company is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products.
Receive News & Ratings for Ampliphi Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampliphi Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.